Ranbaxy gets FDA nod for Glycopyrrolate
MUMBAI (Reuters) - Ranbaxy Laboratories, India's top drugmaker by sales, said on Monday it had final approval from the U.S. Food and Drug Administration to make and market peptic ulcer treatment tablet Glycopyrrolate in two variants.
The tablet is the generic version of Sciele Pharma's Robinul and has annual market sales of $26 million, the Indian firm said in a statement.
Ranbaxy, majority owned by Japan's Daiichi Sankyo, plans to launch the tablet in the December quarter.
(For more news on Reuters Money click in.reuters.com/money)
© Thomson Reuters 2010 All rights reserved
Economy seen growing at 7.2 pct in FY10 - govt
The forecast reinforces the possibility that the government may start to unwind its fiscal stimulus in the budget. Full Article
AIDING GREECE
Eurozone agree in principle to aid Greece - source
Euro zone countries decide to help debt-stricken Greece. Full Article | Video
India
US
UK
